Andrea Staack

Andrea Staack

Auto-generated profile, based on publicly available information

Andrea Staack

Department of Urology, Loma Linda University Health, USA

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in Urology
Verified
Journal Article
Closed access
ASAndrea Staack
Andrea Staack
JVJyotsna Vitale
Jyotsna Vitale
NRNagesh Ragavendra
Nagesh Ragavendra
LRLarissa V. Rodríguez
Larissa V. Rodríguez

8 January 2019 in Neurourology and Urodynamics
Verified
Journal Article
Closed access
PDF file
JYJean Yang
Jean Yang
JCJulie W. Cheng
Julie W. Cheng
HWHillary Wagner
Hillary Wagner
ELEverett Lohman
Everett Lohman
SYSang H. Yang
Sang H. Yang
ASAndrea Staack
Andrea Staack

24 December 2015 in Neurourology and Urodynamics
Verified
Journal Article
Closed access
PDF file
ASAndrea Staack
Andrea Staack
BDBrian Distelberg
Brian Distelberg
ASAmy Schlaifer
Amy Schlaifer
Joan SabatéJoan Sabaté
Joan Sabaté

1 February 2015 in International Journal of Women's Health
Verified
Journal Article
Open access
ASAndrea Staack
Andrea Staack
MMMichelle Marinone
Michelle Marinone
CMChristina P Moldovan
Christina P Moldovan
Stress urinary incontinence is a common, disabling, and costly medical problem that affects approximately 50% of women with urinary incontinence. Suburethral retropubic slings have been developed as a minimally invasive and effective surgical option, and they have been used as a first-line treatment for stress urinary incontinence since 1995. However, complications including vaginal extrusion, erosion, pain, bleeding, infections, lower urinary tract symptoms, urinary retention, and incontinence have been reported with use of the slings. Several companies manufacture sling kits, and the sling kits vary with regard to the composition of the mesh and introducer needle. The aim of this review was to determine which sling kit was most effective for patients, had minimal reported side effects, and was best accepted by patients and surgeons. In a review of the literature, it was found that a total of 38 studies were published between 1995 and 2014 that reported on eight tension-free retropubic sling kits: SPARC, RetroArc, Align, Advantage, Lynx, Desara, Supris, and Gynecare TVT. The Gynecare TVT was the most cited sling kit; the second most cited was the SPARC. This review provides a summary of the studies that have examined positive and negative outcomes of the retropubic tension-free suburethral sling procedure using various sling kits. Overall, the results of the literature review indicated that data from comparisons of the available sling kits are insufficient to make an evidenced-based recommendation. Therefore, the decision regarding which sling kit is appropriate to use in surgery is determined by the medical provider’s preference, training, and past experience, and not by the patient.

10 February 2017 in Neurourology and Urodynamics
Verified
Journal Article
Closed access
PDF file
JSJim K. Shen
Jim K. Shen
DFDaniel Faaborg
Daniel Faaborg
GRGlenn Rouse
Glenn Rouse
IKIsaac Kelly
Isaac Kelly
RLRoger Li
Roger Li
ASAndrea Staack
Andrea Staack

1 January 2021 in Urology Research and Practice
Verified
Journal Article
Closed access
AFAshley Feldkamp
Ashley Feldkamp
AAAkın S. Amasyalı
Akın S. Amasyalı
JGJason Groegler
Jason Groegler
FJForrest Jellison
Forrest Jellison
ASAndrea Staack
Andrea Staack
Objective: Sacral neuromodulation (SNM) is an advanced treatment option for patients with refractory overactive bladder (OAB) symptoms, urinary retention, and bowel disorders; it is usually performed in 2 separate procedures. This study aims to determine a cohort’s progression rate from stage 1 to 2 and predict factors for progression and unplanned device removal or revision. Material and methods: A retrospective review was conducted in patients who underwent SNM at a single institution between June 2012 and May 2019. Progression rates from stage 1 to 2, patient characteristics, and indications for unplanned SNM removal or revision were recorded. Chi-square, Mann-Whitney U, and Fisher’s exact tests were used for data analysis. Results: A total of 128 patients underwent SNM for 1 or more of the following diagnoses: OAB (n=103), urinary retention (n=15), neurogenic bladder dysfunction (n=4), fecal incontinence (n=2), and constipation (n=4). The progression rate to stage 2 was 92.2% (118/128). Patients who failed to progress to stage 2 had additional diagnoses other than OAB, such as urinary retention or bowel disorders (p=0.007). Fifteen patients (12.7%) required SNM removal or revision within 4 years of surgery. Among these patients, the body mass index was significantly lower (p=0.036). Conclusion: Most patients (92.2%) progressed to stage 2. Patients with only OAB symptoms had a higher progression rate to stage 2. Single full-stage procedures may be considered in select patients to reduce morbidity, time, and costs. Cite this article as: Feldkamp A, Amasyalı AS, Groegler J, Jellison F, Staack A. Evaluation of progression from first to second stage sacral neuromodulation and unplanned device removal. Turk J Urol 2021; 47(1): 58-65.